821. A novel peptide protects against diet-induced obesity by suppressing appetite and modulating the gut microbiota.
作者: Zhanzhan Li.;Bing Zhang.;Ning Wang.;Zhenqiang Zuo.;Hong Wei.;Fangqing Zhao.
来源: Gut. 2023年72卷4期686-698页
The obesity epidemic and its metabolic complications continue to be a major global public health threat with limited effective treatments, especially drugs that can be taken orally. Peptides are a promising class of molecules that have gained increased interest for their applications in medicine and biotechnology. In this study, we focused on looking for peptides that can be administrated orally to treat obesity and exploring its mechanisms.
822. Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition.
作者: Julie Bonnereau.;Tristan Courau.;Nicolas Asesio.;Delphine Salfati.;Fatiha Bouhidel.;Hélène Corte.;Sarah Hamoudi.;Nassim Hammoudi.;Julie Lavolé.;Justine Vivier-Chicoteau.;Victor Chardiny.;Leon Maggiori.;Mathieu Blery.;Romain Remark.;Cécile Bonnafous.;Pierre Cattan.;Antoine Toubert.;Purnima Bhat.;Matthieu Allez.;Thomas Aparicio.;Lionel Le Bourhis.
来源: Gut. 2023年72卷4期699-709页
T cells are major effectors of the antitumoural immune response. Their activation by tumour-associated antigens can unleash their proliferation and cytotoxic functions, leading to tumour cell elimination. However, tumour-related immunosuppressive mechanisms including the overexpression of immune checkpoints like programmed cell death protein-1 (PD-1), are also engaged, promoting immune escape. Current immunotherapies targeting these pathways have demonstrated weak efficacy in colorectal cancer (CRC). It is thus crucial to find new targets for immunotherapy in this cancer type.
823. British Society of Gastroenterology guidelines on the management of functional dyspepsia.
作者: Christopher J Black.;Peter A Paine.;Anurag Agrawal.;Imran Aziz.;Maria P Eugenicos.;Lesley A Houghton.;Pali Hungin.;Ross Overshott.;Dipesh H Vasant.;Sheryl Rudd.;Richard C Winning.;Maura Corsetti.;Alexander C Ford.
来源: Gut. 2022年71卷9期1697-1723页
Functional dyspepsia (FD) is a common disorder of gut-brain interaction, affecting approximately 7% of individuals in the community, with most patients managed in primary care. The last British Society of Gastroenterology (BSG) guideline for the management of dyspepsia was published in 1996. In the interim, substantial advances have been made in understanding the complex pathophysiology of FD, and there has been a considerable amount of new evidence published concerning its diagnosis and classification, with the advent of the Rome IV criteria, and management. The primary aim of this guideline, commissioned by the BSG, is to review and summarise the current evidence to inform and guide clinical practice, by providing a practical framework for evidence-based diagnosis and treatment of patients. The approach to investigating the patient presenting with dyspepsia is discussed, and efficacy of drugs in FD summarised based on evidence derived from a comprehensive search of the medical literature, which was used to inform an update of a series of pairwise and network meta-analyses. Specific recommendations have been made according to the Grading of Recommendations Assessment, Development and Evaluation system. These provide both the strength of the recommendations and the overall quality of evidence. Finally, in this guideline, we consider novel treatments that are in development, as well as highlighting areas of unmet need and priorities for future research.
827. Cold versus hot EMR for large duodenal adenomas.
作者: Alessandro Repici.;Antonio Capogreco.;Marco Spadaccini.;Roberta Maselli.;Piera Alessia Galtieri.;Alessandro Fugazza.;Silvia Carrara.;Matteo Colombo.;Guido Schachschal.;Anna Creutzfeldt.;Shahila Perveen Aslam.;Asma Alkandari.;Pradeep Bhandari.;Alexander Meining.;Cesare Hassan.;Thomas Rösch.
来源: Gut. 2022年71卷9期1763-1765页 828. Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study.
作者: Stephan Buch.;Hamish Innes.;Philipp Ludwig Lutz.;Hans Dieter Nischalke.;Jens U Marquardt.;Janett Fischer.;Karl Heinz Weiss.;Jonas Rosendahl.;Astrid Marot.;Marcin Krawczyk.;Markus Casper.;Frank Lammert.;Florian Eyer.;Arndt Vogel.;Silke Marhenke.;Johann von Felden.;Rohini Sharma.;Stephen Rahul Atkinson.;Andrew McQuillin.;Jacob Nattermann.;Clemens Schafmayer.;Andre Franke.;Christian Strassburg.;Marcella Rietschel.;Heidi Altmann.;Stefan Sulk.;Veera Raghavan Thangapandi.;Mario Brosch.;Carolin Lackner.;Rudolf E Stauber.;Ali Canbay.;Alexander Link.;Thomas Reiberger.;Mattias Mandorfer.;Georg Semmler.;Bernhard Scheiner.;Christian Datz.;Stefano Romeo.;Stefano Ginanni Corradini.;William Lucien Irving.;Joanne R Morling.;Indra Neil Guha.;Eleanor Barnes.;M Azim Ansari.;Jocelyn Quistrebert.;Luca Valenti.;Sascha A Müller.;Marsha Yvonne Morgan.;Jean-François Dufour.;Jonel Trebicka.;Thomas Berg.;Pierre Deltenre.;Sebastian Mueller.;Jochen Hampe.;Felix Stickel.
来源: Gut. 2023年72卷2期381-391页
Hepatocellular carcinoma (HCC) often develops in patients with alcohol-related cirrhosis at an annual risk of up to 2.5%. Some host genetic risk factors have been identified but do not account for the majority of the variance in occurrence. This study aimed to identify novel susceptibility loci for the development of HCC in people with alcohol related cirrhosis.
830. Autoimmune gastritis: long-term natural history in naïve Helicobacter pylori-negative patients.
作者: Massimo Rugge.;Ludovica Bricca.;Stefano Guzzinati.;Diana Sacchi.;Marco Pizzi.;Edoardo Savarino.;Fabio Farinati.;Manuel Zorzi.;Matteo Fassan.;Angelo Paolo Dei Tos.;Peter Malfertheiner.;Robert M Genta.;David Y Graham.
来源: Gut. 2023年72卷1期30-38页
Autoimmune gastritis (AIG) is an immunomediated disease targeting parietal cells, eventually resulting in oxyntic-restricted atrophy. This long-term follow-up study aimed at elucidating the natural history, histological phenotype(s), and associated cancer risk of patients with AIG consistently tested H. pylori-negative (naïve H. pylori-negative subjects).
833. Temporality of body mass index, blood tests, comorbidities and medication use as early markers for pancreatic ductal adenocarcinoma (PDAC): a nested case-control study.
作者: Pui San Tan.;Cesar Garriga.;Ashley Clift.;Weiqi Liao.;Martina Patone.;Carol Coupland.;Rachael Bashford-Rogers.;Shivan Sivakumar.;Julia Hippisley-Cox.
来源: Gut. 2023年72卷3期512-521页
Prior studies identified clinical factors associated with increased risk of pancreatic ductal adenocarcinoma (PDAC). However, little is known regarding their time-varying nature, which could inform earlier diagnosis. This study assessed temporality of body mass index (BMI), blood-based markers, comorbidities and medication use with PDAC risk .
834. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D).
作者: Carol Angela Howell.;Anu Kemppinen.;Victoria Allgar.;Matthew Dodd.;Charles H Knowles.;John McLaughlin.;Preeti Pandya.;Peter Whorwell.;Elena Markaryan.;Yan Yiannakou.
来源: Gut. 2022年71卷12期2430-2438页
Irritable bowel syndrome with diarrhoea (IBS-D) is a common and challenging condition that significantly reduces quality of life. Enterosgel (polymethylsiloxane polyhydrate) is an intestinal adsorbent which sequesters harmful molecules and is safe and effective in acute infective diarrhoea. This randomised controlled multicentre trial aimed to investigate its safety and efficacy in patients with IBS-D.
836. Activation of NOTCH signaling via DLL1 is mediated by APE1-redox-dependent NF-κB activation in oesophageal adenocarcinoma.
作者: Lei Chen.;Heng Lu.;Dunfa Peng.;Long Long Cao.;Farah Ballout.;Kannappan Srirmajayam.;Zheng Chen.;Ajaz Bhat.;Timothy C Wang.;Anthony Capobianco.;Jianwen Que.;Oliver Gene McDonald.;Alexander Zaika.;Shutian Zhang.;Wael El-Rifai.
来源: Gut. 2023年72卷3期421-432页
Oesophageal adenocarcinoma (EAC) arises in the setting of Barrett's oesophagus, an intestinal metaplastic precursor lesion that can develop in patients with chronic GERD. Here, we investigated the role of acidic bile salts, the mimicry of reflux, in activation of NOTCH signaling in EAC.
838. Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study.
作者: Sungho Bea.;Han Eol Jeong.;Sohee Park.;Oriana H Y Yu.;Yoosoo Chang.;Juhee Cho.;Dong Hyun Sinn.;Young Min Cho.;Ju-Young Shin.
来源: Gut. 2023年72卷5期1020-1022页 839. Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction.
作者: Kentaro Sugano.;Stuart Jon Spechler.;Emad M El-Omar.;Kenneth E L McColl.;Kaiyo Takubo.;Takuji Gotoda.;Mitsuhiro Fujishiro.;Katsunori Iijima.;Haruhiro Inoue.;Takashi Kawai.;Yoshikazu Kinoshita.;Hiroto Miwa.;Ken-Ichi Mukaisho.;Kazunari Murakami.;Yasuyuki Seto.;Hisao Tajiri.;Shobna Bhatia.;Myung-Gyu Choi.;Rebecca C Fitzgerald.;Kwong Ming Fock.;Khean-Lee Goh.;Khek Yu Ho.;Varocha Mahachai.;Maria O'Donovan.;Robert Odze.;Richard Peek.;Massimo Rugge.;Prateek Sharma.;Jose D Sollano.;Michael Vieth.;Justin Wu.;Ming-Shiang Wu.;Duowu Zou.;Michio Kaminishi.;Peter Malfertheiner.
来源: Gut. 2022年71卷8期1488-1514页
An international meeting was organised to develop consensus on (1) the landmarks to define the gastro-oesophageal junction (GOJ), (2) the occurrence and pathophysiological significance of the cardiac gland, (3) the definition of the gastro-oesophageal junctional zone (GOJZ) and (4) the causes of inflammation, metaplasia and neoplasia occurring in the GOJZ.
840. Current therapies and new developments in NASH.
作者: Jean-François Dufour.;Quentin M Anstee.;Elisabetta Bugianesi.;Stephen Harrison.;Rohit Loomba.;Valerie Paradis.;Herbert Tilg.;Vincent Wai-Sun Wong.;Shira Zelber-Sagi.
来源: Gut. 2022年71卷10期2123-34页
Non-alcoholic steatohepatitis is becoming the most important aetiology for advanced liver disease. There has been important progress in the field in recent years and the complexity of the pathophysiology of NASH is better understood. Multiple non-invasive circulating and imaging biomarkers have been tested. The importance of lifestyle has been recognised and several drugs are being tested in clinical trials. This review addresses the challenges that healthcare professionals face in the management of NASH patients.
|